240 related articles for article (PubMed ID: 16225113)
21. (Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2008 Jan; 18(2):640-4. PubMed ID: 18055202
[TBL] [Abstract][Full Text] [Related]
22. [Tonocardin (doxazosin) in treating lower urinary tract symptoms].
Mazo EB; Chepurov DA
Urologiia; 2003; (3):15-6. PubMed ID: 12846089
[TBL] [Abstract][Full Text] [Related]
23. Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
O'Leary MP
J Urol; 2008 May; 179(5 Suppl):S86. PubMed ID: 18405764
[No Abstract] [Full Text] [Related]
24. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy.
Koseoglu H; Aslan G; Ozdemir I; Esen A
Urology; 2006 Jun; 67(6):1188-92. PubMed ID: 16750254
[TBL] [Abstract][Full Text] [Related]
25. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
26. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
Parsons JK
J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
[TBL] [Abstract][Full Text] [Related]
27. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting.
Rosenberg MT; Staskin DR; Kaplan SA; MacDiarmid SA; Newman DK; Ohl DA
Int J Clin Pract; 2007 Sep; 61(9):1535-46. PubMed ID: 17627768
[TBL] [Abstract][Full Text] [Related]
28. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
Fine SR; Ginsberg P
J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
[TBL] [Abstract][Full Text] [Related]
29. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
30. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
[TBL] [Abstract][Full Text] [Related]
31. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
[TBL] [Abstract][Full Text] [Related]
32. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
33. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
Barqawi AB; Myers JB; O'Donnell C; Crawford ED
BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
[TBL] [Abstract][Full Text] [Related]
34. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.
Barendrecht MM; Koopmans RP; de la Rosette JJ; Michel MC
BJU Int; 2005 Jun; 95 Suppl 4():19-28. PubMed ID: 15871732
[No Abstract] [Full Text] [Related]
35. [Relation between hypertension and clinical cases of benign prostatic hyperplasia].
Nicolás Torralba JA; Tornero Ruiz J; Bañón Pérez V; Server Pastor G; López Cubillana P; Pérez Albacete M
Arch Esp Urol; 2003 May; 56(4):355-8. PubMed ID: 12830607
[TBL] [Abstract][Full Text] [Related]
36. (Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
Bioorg Med Chem Lett; 2007 Jun; 17(12):3292-7. PubMed ID: 17452102
[TBL] [Abstract][Full Text] [Related]
37. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
38. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Resnick MI; Roehrborn CG
Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
[TBL] [Abstract][Full Text] [Related]
39. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
40. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?
Gravas S; Melekos MD
Curr Opin Urol; 2009 Jan; 19(1):49-54. PubMed ID: 19057216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
